Approved (FDA) as single agent since 2017 in advanced platinum-sensitive ovarian cancerPhase III as single agent in BRCAmut/HER2-ve mutated TNBC, In combination with Dostarlimab or bevacizumab or atezolizumab in ovarian cancer, with pembrolizumab in NSCLC, with abriratrone and prednisone in HRR gene mutated CRPC, in combination with Dostarlimab. Here, ERBB2 is linked to ovarian carcinoma.